Charles Explorer logo
🇬🇧
Search for publications relevant for "point-of-care tests"

Budesonid potvrdil efekt v léčbě IgA nefropatie ve studii NefIgArd: konec éry systémových kortikosteroidů?

Publication at First Faculty of Medicine |
2023
1 person

This text is not available in the current language. Showing version "cs".Abstract

Souhrn s komentářem. Citace: Barratt J, Lafayette R, Kristensen J, et al.; for the NefIgArd Trial Investigators.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2023;103:391-40.

Person